Approval · Notice of Compliance 14547 · 2013
MINT-CLOPIDOGREL: Notice of Compliance 14547
Issued July 12, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14547
- Date
- July 12, 2013
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Platelet aggregation inhibitor
- Canadian reference product
- PLAVIX (Sanofi-Aventis Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-CLOPIDOGREL | 02408910 | Marketed |
| MINT-CLOPIDOGREL | 02408929 | Approved |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB
- CLOPIDOGREL BISULFATE 300 MG per TAB